Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: February 28, 2013
Last updated: February 5, 2015
Last verified: January 2015

This open label, single-arm, non-controlled, multicentre study will determine the effect of ambrisentan on exercise capacity (6MWT) in Chinese subjects with PAH. The study consists of a screening period of 4 weeks, a 12-week primary evaluation period (PEP) and a 12-week dose-adjustment period (DAP). Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks (PEP).

Condition Intervention Phase
Vascular Disease
Drug: ambrisentan
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • 6MWT [ Time Frame: 12 weeks and 24 weeks ] [ Designated as safety issue: No ]
    walk distance during 6 minutes change from baseline

Secondary Outcome Measures:
  • WHO function class [ Time Frame: 12 weeks and 24 weeks ] [ Designated as safety issue: No ]
    WHO function class change from baseline

  • BDI [ Time Frame: 12 weeks and 24 weeks ] [ Designated as safety issue: No ]
    borg dysnea index change from baseline

  • NT-proBNP [ Time Frame: 12 weeks and 24 weeks ] [ Designated as safety issue: No ]
    NT-proBNP change from baseline

  • Clinical worsening of PAH [ Time Frame: 12 weeks and 24 weeks ] [ Designated as safety issue: Yes ]
    time from baseline to the first occurrence of death, lung transplantation, hospitalisation for PAH treatment, atrial septostomy or investigational product discontinuation due to change to other PAH treatment

  • Safety and tolerability [ Time Frame: 12 weks and 24 weeks ] [ Designated as safety issue: Yes ]
    AEs, serious AEs, AEs leading to discontinuation, physical examination, 12-lead electrocardiogram parameters, vital signs parameters (systolic and diastolic blood pressure, heart rate and oral temperature), liver function tests and clinical laboratory parameters

Enrollment: 134
Study Start Date: December 2012
Study Completion Date: August 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ambrisentan
ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
Drug: ambrisentan
Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks

Detailed Description:

Pulmonary arterial hypertension (PAH) consists of a group of progressive and incurable diseases of the pulmonary vasculature. These are characterised by profound vasoconstriction and abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries, which leads to a progressive increase in pulmonary vascular resistance (PVR) and sustained elevations in pulmonary artery pressure (PAP). A variety of drug classes have been used to treat PAH but no single compound has yet been shown to be effective in treating all patients with the disease. Three widely used treatment options are calcium channel blockers (CCBs), diuretics and anticoagulants but all have varying responses.There is a lack of clinical data on ambrisentan among the Chinese population,Ambrisentan is conditionally approved for the treatment of PAH in China.A clinical trial with a minimum of 100 patients in the ambrisentan arm was requested by SFDA.Several PAH medications have been approved in China, so a placebo-controlled study is not ethically appropriate while an active control non-inferiority design is unfeasible due to sample size requirements and inconsistency in indications.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed written informed consent prior to beginning study-related procedures.
  • Subject must be between 18-75 years of age, inclusive, at the Screening Visit.
  • Subjects must weight ≥40 kg at the Screening Visit.
  • Subjects must have symptomatic or severe PAH (WHO functional class II or III) and be categorised as class 1 PAH (defined by the Updated Clinical Classification of Pulmonary Hypertension 2009), due to iPAH, congenital heart disease-congenital heart defects repaired greater than 1 year prior to screening (i.e., atrial septal defects, ventricular septal defects or patent ductus arteriosus) or CTD-related PAH (e.g., limited scleroderma, diffuse scleroderma, mixed CTD, systemic lupus erythematosus or overlap syndrome).

NOTE: subjects with portopulmonary hypertension and pulmonary venoocclusive disease are NOT eligible for the study.

  • Subjects must have had a right heart catheterisation within 6 months prior to screening and meet all of the following haemodynamic criteria:

    1. Mean PAP ≥ 25 mmHg.
    2. A PVR ≥ 240 dyn/sec/cm5.
    3. A PCWP or left ventricular (LV) end-diastolic pressure of ≤ 15 mmHg.
  • Subjects must be able to walk a distance of at least 150 m but no more than 450 m. In addition, the screening and baseline 6MWT test values must not vary by greater than 10% (calculated using (baseline - screening)/screening with the result to be between -0.1 and 0.1).
  • Subjects must meet both of the following pulmonary function criteria. The tests should have been completed no more than 24 weeks prior to the Screening Visit, if not performed within the previous 24 weeks, the test must be completed at Day 0:

    1. Total lung capacity (TLC) ≥ 60% of predicted normal.
    2. Forced expiratory volume in one second (FEV1) ≥ 55% of predicted normal.
  • Subjects receiving CCBs must be on stable therapy (i.e., the dose level does not need to change to maintain disease control) for at least 1 month prior to the Screening Visit.
  • Subjects receiving 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (i.e., statins) must be on stable therapy (i.e., the dose level does not need to change to maintain disease control) for at least 12 weeks prior to the Screening Visit.
  • Female subjects of childbearing potential must have a negative pregnancy test at the Screening Visit and Day 0.
  • Female subjects of childbearing potential who are sexually active must agree to use two reliable methods of contraception (as described in Appendix 3 ) from the Screening Visit until study completion and for at least 30 days following the last dose of IP. Subjects who have had a Copper T 380A intrauterine device (IUD) or LNg 20 IUD inserted are not required to use an additional method of contraception.
  • Subject must agree not to participate in a clinical study involving another IP or device throughout this study.

Exclusion Criteria:

  • The subject has received PAH therapy (PDE-5 inhibitors, ERA, chronic prostanoid*) within 4 weeks prior to the Screening Visit.

    *Prostanoid use is classed as chronic when treatment continues for more than 7 days.

  • The subject has received intravenous inotropes (e.g., dopamine, dobutamine) within 2 weeks prior to the Screening Visit.
  • The subject has previously been discontinued from ERA treatment (e.g., bosentan) due to safety or tolerance issues other than those associated with liver function abnormalities.
  • The subject has a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value that is >2 x the upper limit of normal (ULN) at the Screening Visit.
  • The subject has serum bilirubin value that is >1.5 x ULN at the Screening Visit.
  • The subject has severe hepatic impairment (Child-Pugh class C with or without cirrhosis) at the Screening Visit.
  • The subject has severe renal impairment (creatinine clearance <30 mL/min) at the Screening Visit.
  • The subject has clinically significant anaemia, defined as haemoglobin concentration <10 g/dL or haematocrit <30% at the Screening Visit.
  • The subject has a laboratory result, physical examination finding, medical history incident or other finding, which is a contraindication for treatment with an ERA. Contraindications for treatment include, but are not limited to, evidence of elevated liver functions test or previously experiencing an event that would be defined as a serious AE (SAE) in a clinical trial (see Section, which was attributed to treatment with an ERA.
  • The subject has severe hypotension (either diastolic blood pressure <50 mmHg or systolic blood pressure <90 mmHg).
  • The subject has, in the opinion of the Investigator, clinically significant aortic or mitral valve disease, pericardial constriction, restrictive or congestive cardiomyopathy, life-threatening cardiac arrhythmias, significant LV dysfunction (defined as LV ejection fraction <45%), LV outflow obstruction, symptomatic coronary artery disease, autonomic hypotension or fluid depletion.
  • The subject has a history of malignancies within the past 5 years, with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix.
  • The subject has cardiovascular, liver, renal, haematological, gastrointestinal, immunological, endocrine, metabolic or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject.
  • A female subject who is pregnant or breastfeeding.
  • The subject has demonstrated non-compliance with previous medical regimens or is unable to comply with the procedures described in this protocol.
  • The subject has a history of abusing alcohol or drugs of abuse (including amphetamines, methamphetamines, opiates, cannabinoids, cocaine, benzodiazepines or barbiturates) within 12 months prior to the Screening Visit. Use of such drugs if prescribed by a Doctor and used according to the prescription would not exclude a subject.
  • The subject has participated in a clinical study involving another IP or device within 4 weeks or five half-lives of an IP, whichever is longer, before the Screening Visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01808313

China, Heilongjiang
GSK Investigational Site
Harbin, Heilongjiang, China, 150001
China, Hubei
GSK Investigational Site
Wuhan, Hubei, China, 430022
China, Hunan
GSK Investigational Site
Hunan, Hunan, China, 410008
China, Jilin
GSK Investigational Site
Changchun, Jilin, China, 130021
China, Shaanxi
GSK Investigational Site
Xian, Shaanxi, China, 710032
China, Shandong
GSK Investigational Site
Jinan, Shandong, China, 250012
GSK Investigational Site
Beijing, China, 100034
GSK Investigational Site
Beijing, China, 100032
GSK Investigational Site
Beijing, China, 100037
GSK Investigational Site
Beijing, China, 100038
GSK Investigational Site
Shanghai, China, 200001
GSK Investigational Site
Shanghai, China, 200433
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01808313     History of Changes
Other Study ID Numbers: 115812
Study First Received: February 28, 2013
Last Updated: February 5, 2015
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 03, 2015